SCHEMBL24327587

SCHEMBL24327587

Cc1cnc(Cl)nc1Nc1cccc2c1N(S(C)(=O)=O)CC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 9/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
TUBB4A P04350 5/20 0.36
TUBB P07437 5/20 0.36
TUBA3C P0DPH7 5/20 0.36
TUBA1B P68363 5/20 0.36
TUBA4A P68366 5/20 0.36
TUBB4B P68371 5/20 0.36
TUBB3 Q13509 5/20 0.36
TUBB2A Q13885 5/20 0.36
TUBB8 Q3ZCM7 5/20 0.36
TUBA3E Q6PEY2 5/20 0.36
TUBA1A Q71U36 5/20 0.36
TUBA1C Q9BQE3 5/20 0.36
TUBB6 Q9BUF5 5/20 0.36
TUBB2B Q9BVA1 5/20 0.36
TUBB1 Q9H4B7 5/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29661472 1.00 BRD4 (0.37) BRD4MEN1KMT2ATUBB4ATUBB
SCHEMBL24327468 0.90 CDK9 (0.43) NPC1RAB9ACDK9CDK7CCNK
SCHEMBL29661342 0.90 CDK9 (0.43) NPC1RAB9ACDK9CDK7CCNK
SCHEMBL24328356 0.88 GLO1 (0.41) BRD4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL29661413 0.88 GLO1 (0.41) BRD4TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL24327315 0.88 ZAP70 (0.41) MEN1KMT2ATUBB4ATUBBTUBA3C
SCHEMBL29661317 0.88 ZAP70 (0.41) MEN1KMT2ATUBB4ATUBBTUBA3C
SCHEMBL30942615 0.86 CHEK1 (0.42) BRD4CDK2
SCHEMBL24327335 0.86 TUBB4A (0.42) MEN1KMT2ATUBB4ATUBBTUBA3C
SCHEMBL29661398 0.86 TUBB4A (0.42) MEN1KMT2ATUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117794914-A Pyrimidine-2, 4-diamine derivatives, process for preparing the same, and pharmaceutical composition for preventing or treating cancer comprising the same as active ingredient 韩国化学研究院 2024-03-29 CN disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEONE MEDICINES I GMBH (CH) 2023-11-23 US disclosed
WO-2022063106-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS BEIGENE, LTD. (KY) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373960-A1 INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS EGFR, ERBB2, ERBB4 BRD4 517/4885MEN1 1963/4885KMT2A 2570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.